PsychedelicNewsBreaks

ThursdayApr 07, 2022 2:21 pm

PsychedelicNewsBreaks – Why Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves,” a recent article reads. Silo Pharma is involved in a sponsored study with Maastricht University…

Continue Reading

WednesdayApr 06, 2022 2:20 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Expanding Boundaries in Research of New Products

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is continually expanding its efforts to conduct and encourage even more research and education in support of high-quality products, such as psychedelics and cannabis, for the market. The company understands that research is integral for the rapidly developing psychedelics and cannabis industries, and for psychedelics to be widely adopted for treating mental issues. In addition, the company is helping reframe the psychedelic conversation while being at the forefront of the ongoing psychedelics renaissance. A recent article reads, “Delic’s focus on research is moving society closer to the full adoption…

Continue Reading

WednesdayApr 06, 2022 12:42 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be represented at the Benzinga Psychedelics Capital Conference. The premier event is scheduled for April 19, 2022, and will be held in Miami Beach, Florida. Cybin CEO Doug Drysdale will present a fireside chat and will also be a member of a panel discussion. Drysdale’s chat is slated to start at 1:10 p.m. ET. The panel discussion, which is titled “Short, Medium, and Long Term Catalysts in Psychedelics,” is scheduled for 3:10 p.m. ET. Archives versions of both events will be available on the company’s…

Continue Reading

FridayApr 01, 2022 1:59 pm

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Therapeutics Inc. Achieves New Milestone

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that Adelia Therapeutics, a wholly controlled subsidiary of Cybin, has achieved the milestone identified as Year 1, Q2 (iv) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020. The transaction agreement was among Cybin, Cybin Corp., Cybin US Holdings Inc. (the “acquiror”), a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia. “We are extremely pleased with the rate and speed in which our team has been able to achieve these milestones that support our pipeline…

Continue Reading

FridayApr 01, 2022 1:27 pm

PsychedelicNewsBreaks – LFTD Partners Inc. (LIFD) Announces Record Revenue for Q4 and Full Year 2021

LFTD Partners (OTCQB: LIFD), the corporate parent of leading cannabis and psychedelics-lifestyle and consumer packaged goods company Lifted Made, reported record revenue for fourth quarter and full year 2021, and its sixth consecutive quarter of positive GAAP-basis earnings per share. Among the financial highlights for the 2021 fiscal year, LFTD Partners reported a 492% increase in revenue to $31,656,932, up from $5,344,320 in 2020. “Our tremendous growth and profitability during 2021 was a reflection of the team and infrastructure that we have built over the years and is a testament to the power of a true consumer-run business,” said Nicholas…

Continue Reading

ThursdayMar 31, 2022 2:23 pm

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Announces Filing of Year-End 2021 Results

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the filing of its Annual Report on Form 20-F for the year ended Dec. 31, 2021, audited financial results for the fourth quarter and full year then ended and accompanying management discussion and analysis. According to the announcement, the filings are available for review under the company's SEDAR profile at www.sedar.com and its EDGAR profile at www.sec.gov. To view the full press release, visit https://ibn.fm/LPlQS About FSD Pharma Inc. FSD Pharma is a biotechnology company…

Continue Reading

ThursdayMar 31, 2022 1:03 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Commencement of Kernel Flow(R) Feasibility Study, Marking Exciting Moment for Psychedelic Drug Development

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that the first visit has been conducted in a Cybin-sponsored feasibility study. The study will focus on evaluating Kernel’s quantitative neuroimaging technology, Flow, to measure ketamine’s psychedelic effects on cerebral cortex hemodynamics. “The commencement of the Kernel feasibility study marks a truly exciting moment, not only for Cybin and Kernel, but also for the entire field of psychedelic drug development. To this point, studies have had to rely on subjective patient reporting,” said Cybin CEO Doug Drysdale. “By deploying the innovative Flow technology,…

Continue Reading

ThursdayMar 31, 2022 11:19 am

PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Enters Agreement to Significantly Advance Technologies ‘Closer to the Clinic’

Silo Pharma (OTCQB: SILO) is a developmental stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. Silo Pharma today announced its entry into an agreement with Frontage Laboratories, a contract research organization (“CRO”) providing integrated, science-driven, product development services throughout the drug discovery and development process that enable life science companies to achieve their drug development goals. “This agreement significantly advances our Central Nervous System Peptide, SPU-16, and our Joint Homing Peptide, SPU-21 technologies closer to the clinic,” said Eric Weisblum, CEO of Silo Pharma. “These solutions have the potential to enhance the therapeutic effect of current…

Continue Reading

ThursdayMar 31, 2022 11:10 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces New Clinic Openings as Company’s Expansion Accelerates

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, is opening Ketamine Wellness Centers (“KWC”) in Salt Lake City and Reno, Nevada, with additional locations planned to open this year. The company also announced that it is adding SPRAVATO(R), the first FDA-approved nasal spray, as a treatment option at three of its ketamine centers; the spray is intended to treat adults with treatment-resistant depression and depressive symptoms of major depressive disorder. In addition, the the company’s Delic Labs received Health Canada 56 exemptions to perform research and development work for several substances, including MDMA,…

Continue Reading

WednesdayMar 30, 2022 12:59 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Subsidiary Expands Treatment Options to Add FDA-Approved Esketamine Nasal Spray

Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary, Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S., has expanded its treatment options to include SPRAVATO(R) nasal spray. KWC clinics located in Houston, Las Vegas and Seattle will begin offering this treatment option on April 1. According to the announcement, SPRAVATO is taken with an oral antidepressant and is the first FDA-approved esketamine nasal spray for adults with treatment-resistant depression (“TRD”) or to treat depressive symptoms in adults with major depressive disorder (“MDD”) with suicidal thoughts or actions. Patients interested in the treatment option will first undergo…

Continue Reading